May 25, 2017 1:42 PM ET


Company Overview of Five Prime Therapeutics, Inc.

Key Executives for Five Prime Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Lewis T. Williams M.D., Ph.D.34 RelationshipsFounder, Chairman, Chief Executive Officer and President67
Marc L. Belsky No RelationshipsChief Financial Officer and Senior Vice President61
Aron Marc Knickerbocker 19 RelationshipsChief Operating Officer and Director47
Kevin P. Baker Ph.D.No RelationshipsSenior Vice President of Development Sciences55
Luis Borges Ph.D.No RelationshipsSenior Vice President of Research54
View More Key Executives

Five Prime Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Lewis T. Williams M.D., Ph.D. 34 RelationshipsFive Prime Therapeutics, Inc.67
Aron Marc Knickerbocker 19 RelationshipsFive Prime Therapeutics, Inc.47
Franklin M. Berger CFA, BA, MA, MBA 105 RelationshipsFive Prime Therapeutics, Inc.67
Peder K. Jensen M.D. 45 RelationshipsFive Prime Therapeutics, Inc.61
Kapil Dhingra M.B.B.S.,M.D., Ph.D. 139 RelationshipsForbion Capital Partners57
View All Board Members

Five Prime Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Compensation Committee M.D.Sheila Gujrathi19 Relationships3 Executives
Nominating Committee M.D.Peder K. Jensen45 Relationships1 Executives
Corporate Governance Committee M.D.Peder K. Jensen45 Relationships1 Executives
Management/Organization Development Committee M.D.Sheila Gujrathi19 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Total Short Term Compensation$32.2M
Not meaningful
Total Value of Options$885.8K
Compensation as of Fiscal Year 2016
Five Prime Therapeutics, Inc. CEO Compensation
Industry Average


Neuralstem, Inc. Announces Resignation of Catherine Sohn from the Board of Directors
May 24, 2017 8:01 PM ET
Medigene AG Announces New Supervisory Board Members
May 24, 2017 4:01 PM ET
Asterias Biotherapeutics, Inc. Announces Executive Changes
May 23, 2017 8:10 PM ET
Aldevron Names Henry Hebel as New Chief Operating Officer
May 23, 2017 4:36 PM ET
Juno Therapeutics Appoints Jay Flatley to Board of Directors
May 23, 2017 1:00 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Five Prime Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at